Literature DB >> 8078931

Ras mediates Src but not epidermal growth factor-receptor tyrosine kinase signaling pathways in GH4 neuroendocrine cells.

C A Pickett1, A Gutierrez-Hartmann.   

Abstract

p21Ras has been implicated as a critical signaling component in mediating the effects of many growth factor receptor/tyrosine kinases on cell growth and differentiation. However, the precise functional role of Ras in establishing a cell-specific transcriptional response to a ubiquitous growth factor remains unclear. We have utilized a transient cotransfection model system in epidermal growth factor (EGF)-responsive cultured GH4 rat pituitary neuroendocrine cells to investigate the role of Ras in coupling EGF receptor (EGF-R) and v-Src tyrosine kinase signals to the activation of a cell-specific promoter for the rat (r) prolactin (PRL) gene. A significant dose- and time-dependent EGF stimulation of the transfected rPRL promoter was obtained. A similar degree of activation of the rPRL promoter was obtained by cotransfection of a plasmid encoding v-Src. Cotransfection of a construct encoding the dominant-negative Ras, N17Ras, produced almost complete inhibition of v-Src-induced rPRL promoter activity, while EGF-stimulated rPRL promoter activity was unaffected. Similarly, EGF activation of a c-Fos promoter was unaffected by N17Ras, while v-Src activation was blocked. Hence, using transcription regulation as a functional assay, we show that Ras is not required for the EGF-mediated control of the rPRL and c-Fos promoters, whereas Ras is critical in mediating the v-Src effects to these two promoters. These observations emphasize that, despite current biochemical data linking the EGF-R and Ras pathways, the functional significance of such an interaction should be analyzed in a biologically relevant manner and may differ as a function of cell type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078931      PMCID: PMC44656          DOI: 10.1073/pnas.91.18.8612

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

2.  Effect of a dominant inhibitory Ha-ras mutation on mitogenic signal transduction in NIH 3T3 cells.

Authors:  H Cai; J Szeberényi; G M Cooper
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

3.  Two different cis-active elements transfer the transcriptional effects of both EGF and phorbol esters.

Authors:  H P Elsholtz; H J Mangalam; E Potter; V R Albert; S Supowit; R M Evans; M G Rosenfeld
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

4.  Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

5.  Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response.

Authors:  L K Johnson; J D Baxter; I Vlodavsky; D Gospodarowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

6.  Tumor-promoting phorbol esters affect production of prolactin and growth hormone by rat pituitary cells.

Authors:  R Osborne; A H Tashjian
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

7.  Epidermal growth factor rapidly stimulates prolactin gene transcription.

Authors:  G H Murdoch; E Potter; A K Nicolaisen; R M Evans; M G Rosenfeld
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

8.  Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.

Authors:  W S Chen; C S Lazar; M Poenie; R Y Tsien; G N Gill; M G Rosenfeld
Journal:  Nature       Date:  1987 Aug 27-Sep 2       Impact factor: 49.962

9.  Identification of the functional components of the Ras signaling pathway regulating pituitary cell-specific gene expression.

Authors:  K E Conrad; J M Oberwetter; R Vaillancourt; G L Johnson; A Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

10.  Requirement for c-ras proteins during viral oncogene transformation.

Authors:  M R Smith; S J DeGudicibus; D W Stacey
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

View more
  7 in total

1.  The 26-amino acid beta-motif of the Pit-1beta transcription factor is a dominant and independent repressor domain.

Authors:  Matthew D Jonsen; Dawn L Duval; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2009-06-25

2.  Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression.

Authors:  A P Bradford; C Wasylyk; B Wasylyk; A Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 3.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

Review 4.  Prolactin and mammary gland development.

Authors:  N D Horseman
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

5.  c-Src signaling induced by the adapters Sin and Cas is mediated by Rap1 GTPase.

Authors:  L Xing; C Ge; R Zeltser; G Maskevitch; B J Mayer; K Alexandropoulos
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Epidermal growth factor and Ras regulate gene expression in GH4 pituitary cells by separate, antagonistic signal transduction pathways.

Authors:  C A Pickett; A Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

7.  Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes.

Authors:  P Levy; A Munier; S Baron-Delage; Y Di Gioia; C Gespach; J Capeau; G Cherqui
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.